Learn and explore. Enjoy both days.

Hemp cultivation under Japan's new regulatory framework began in 2025, but entering the industry still involves many hurdles. What stands in the way, and what is needed, for more growers to join and for the industry to develop? Drawing on the situation in Mongolia, Austria and Singapore, this session explores the keys to growing the industry.

• Naoko MikiMCDirector, GREEN ZONE JAPAN
• Anar ArturFounder, CBD Mongolia LLC
• THTakeshi HarigayaDirector, Kanna Research Institute
• Aya AmmiChair, HEMP HUB
• Elena YanevaCEO & co-founder, Hempstatic
• Dr. Patrick ChinFounder & CEO, Clairvoyant Lab
• Stephan MoreelsManaging Director, Control Union (Thailand) Co. Ltd
• Paul BenhaimFounder, Cannabis Psychedelics

Overseas, medicines made with cannabis-derived ingredients, such as Epidiolex for epilepsy and Sativex for multiple sclerosis, are already used in clinical practice. In Japan, however, challenges remain on the road to practical use, from legal regulation to the development and approval systems. This session shares the status of bringing Epidiolex to Japan, the current state of specified clinical research and AMED projects, and moves to introduce products developed overseas, and discusses what is needed to deliver cannabis-derived medicines to patients in Japan.

• Yuji MasatakaMCRepresentative Director, GREEN ZONE JAPAN
• Ichiro TakumiChair, Japanese Clinical Association of Cannabinoids (JCAC)
• Kohei YamadaFounder & CEO, KISEKI GROUP CORP.

In cancer care, how we address pain, nausea, anxiety and delirium — and how we support the quality of life of patients and their families — matters as much as the treatment itself. Cannabinoids have been applied and studied in palliative and supportive care overseas, and a change in the law has now opened the way for cannabis-derived medicines in Japan. This session brings together long experience in palliative care and cannabinoid therapy in the United States and the perspective of psycho-oncology in Japan, where the focus is on delirium, cognitive function and psychological symptoms in cancer patients, to discuss where medical cannabis and cancer care stand today and what can be considered in Japanese clinical practice.

• Naoko MikiMCDirector, GREEN ZONE JAPAN
• Kohei YamadaFounder & CEO, KISEKI GROUP CORP.
• Mary Szomjassy BrownCo-Founder & COO, TrueImports
• Asao OgawaChief, Department of Psycho-Oncology, National Cancer Center Hospital East

CBN has been regulated as a designated substance since June 2026. Yet a path remains for people with a recognised therapeutic need to keep using it as a 'legitimate use'. Through the design of the system and how eligibility is assessed in practice, the challenges faced by doctors who issue medical certificates, and the voices of patients themselves, this session examines from several angles where CBN regulation stands today and the 'inconvenient truths' that have surfaced in its shadow.

• Yuji MasatakaMCRepresentative Director, GREEN ZONE JAPAN
• Ichiro TakumiChair, Japanese Clinical Association of Cannabinoids (JCAC)
• Kosuke HikitaPhysician, Medical Green Clinic
• Yuuka OsadaPhysician, Den-en-chofu Osada Orthopedic Clinic (Comprehensive Preventive Medicine)
• 菊池 星来Medical CBN

As the number of places where medical cannabis and hemp-derived CBD products are legal grows, and rules for regulation and oversight take shape, there is still no shortage of operators who try to get around them. Sound quality control and traceability are challenges that producers and distributors cannot avoid if they are to deliver compliant, high-quality products to consumers. Centred on the quality management system developed by TrueImports, this session discusses the quality control needed to build a healthy market.

• Naoko MikiMCDirector, GREEN ZONE JAPAN
• Kohei YamadaFounder & CEO, KISEKI GROUP CORP.
• Mary Szomjassy BrownCo-Founder & COO, TrueImports
• Michael HadjisavasHead of Life Sciences and Healthcare, p-Chip Corporation
• Stephan MoreelsManaging Director, Control Union (Thailand) Co. Ltd
• Kaito AmanoOperations Manager, KCA Labs Japan LLC

Comprehensive regulation of hemp-derived CBD products has stalled in many countries. In the United States, the THC content of hemp-derived CBD products will be restricted from December, and many products now on the market are expected to become unsellable. This session examines the pros and cons of this THC regulation and its impact on the CBD market, particularly for people who use CBD for medical purposes.

• Naoko MikiMCDirector, GREEN ZONE JAPAN
• Dr. Mark G. DarkoPresident/CEO, Chamber of Cannabis Industry-Ghana
• Laura RamosCo-founder & Editor-in-Chief, CannaReporter
• Morris BeegleFounder, Industrial Hemp International
• Sharon Deidre Leyson (Dydy)Secretary General, Asia International Hemp Federation (AIHF)

For Japan's hemp industry to grow sustainably, the question is not only what we can make, but what we should make to reach consumers. This session brings together practitioners exploring hemp across food, traditional industries, textiles and apparel, and material development. Through their work, we discuss the ideas, challenges and possibilities needed to turn Japanese hemp into products that sell and products that people choose.

• Yuji MasatakaMCRepresentative Director, GREEN ZONE JAPAN
• Takamasa KitamuraASAFUKU Co., Ltd.
• Shohei OkudaRepresentative Director, GUE TRADING Inc.
• Eisuke MurogaPresident & Representative Director, Yawataya Isogoro Co., Ltd.
• Takehiro DaitohHead of Business, weavearth Linen and Hemp

Participating companies, presentation order, individual speaking times and the moderator are being arranged.

Cannabis has been used as a medicinal herb around the world since ancient times, and it contains many plant compounds besides cannabinoids. Terpenes have drawn attention in the cannabis world only relatively recently, yet in herbal medicine they have long played an important role. When we see cannabis as a medicinal herb, what can we expect from terpenes? This session explores their potential.

• Naoko MikiMCDirector, GREEN ZONE JAPAN
• Shinichiro HayashiRepresentative, Green Flask Co., Ltd.
• Kazushige MatsumotoEditorial & Operations Support, HempTODAY JAPAN